查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1159188

黑色素細胞蛋白質PMEL的全球市場(2022年～2028年)

Melanocyte Protein PMEL Market 2022-2028
出版日期: | 出版商: Orion Market Research | 英文 125 Pages | 商品交期: 2-3個工作天內

價格

全球黑色素細胞蛋白質PMEL的市場規模在預測期間內預計將以大幅年複合成長率增長。全球黑色素瘤的盛行率上升，促進了市場的成長。

本報告提供全球黑色素細胞蛋白質PMEL市場相關調查分析，提供市場概要，競爭情形，市場分析，企業簡介等系統性資訊。

目錄

第1章 報告概要

第2章 市場概要與洞察

  • 調查範圍
  • 分析師的洞察和目前市場趨勢

第3章 競爭情形

  • ImmunoCellular Therapeutics, Ltd.
  • Vault Pharma Inc.
  • Antigen Express, Inc.
  • Immunomic Therapeutics, Inc.
  • Scancell Holdings Plc
  • 主要策略分析
  • COVID-19對主要企業帶來的影響

第4章 市場區隔

  • 全球黑色素細胞蛋白質PMEL市場:各類型
    • AE-M疫苗
    • SCIB-1
    • VPI-121
    • 其他
  • 全球黑色素細胞蛋白質PMEL市場:各用途
    • 多形性膠質母細胞瘤
    • 黑色素瘤
    • 轉移性黑色素瘤

第5章 地區分析

  • 北美
    • 美國
    • 加拿大
  • 歐洲
    • 英國
    • 德國
    • 義大利
    • 西班牙
    • 法國
    • 其他歐洲
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 韓國
    • 其他亞太地區
  • 全球其他地區

第6章 企業簡介

  • Amgen Inc.
  • Bristol Myers Squibb
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline plc
  • Merck & Co.
  • Novartis AG
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Sarabhai Piramal Pharmaceuticals Ltd.
Product Code: OMR2026071

Global Melanocyte Protein PMEL Market Size, Share and Trends Analysis Report by Type (AE-M vaccine, SCIB-1, VPI-121, and Others) by Application (Glioblastoma Multiforme, Melanoma and Metastatic Melanoma)Forecast Period (2022-2028)

The global melanocyte protein PMEL market is expected to rise at a considerable CAGR during the forecast period (2022-2028). The major factor driving the growth of the market includes the rising prevalence of melanoma across the globe. According to the American Cancer Society, in 2022, an estimated 99,780 new melanomas will be diagnosed globally. Out of which about 57,180 new cases will be diagnosed in men and 42,600 in women. PMEL mutations, on the other hand, have been observed to modify pheomelanic pigmentation in bovines, resulting in coat color dilution. Computer-assisted diagnosis techniques (dermoscopy and spectroscopy-based) for diagnosing skin cancer in adults: In this research, artificial intelligence is used in computer-assisted diagnostic (CAD) systems to analyze lesion data and make a skin cancer diagnosis. The conclusion of the research was that all CAD forms show great sensitivity in highly selected patient populations, and could be used as a backup for specialist diagnosis to enable to reduce the chance of missing melanomas. New clinical trials are now testing other immunotherapy drugs and combinations in SCC (Squamous Cell Carcinoma) and BCC(Basal Cell Carcinoma) can be future opportunities for the market.

The global melanocyte protein PMEL market is segmented based on type and application. Based on type, the market is segmented into AE-M vaccine, SCIB-1, VPI-121, and Others. Based on application the market is segmented into glioblastoma multiforme, melanoma, and metastatic melanoma. GBM(Glioblastoma Multiforme) is currently treated with chemotherapy using the medication temozolomide. During radiation therapy, the medicine is usually given every day, and then for six cycles afterward in the maintenance phase.

The global melanocyte protein PMEL market is further segmented based on geography Including North America (the US, and Canada), Europe (Italy, Spain, Germany, France, and Others), Asia-Pacific (India, China, Japan, South Korea, and Others), and the Rest of the World (the Middle East and Africa, and Latin America).

The major companies serving the global melanocyte protein PMEL market include ImmunoCellular Therapeutics, Ltd., Vault Pharma Inc., Antigen Express, Inc., Immunomic Therapeutics, Inc., Scancell Holdings Plc, and others. To enhance their market share, industry participants are employing a number of critical techniques. For instance, Sarabhai Piramal Pharmaceuticals Ltd. made the chemotherapy drug FLUOROURACIL, 5-FUthat is used to treat cancer. It is applied to the skin to treat skin cancer and certain skin diseases that have the potential to become cancerous.

Research Methodology

The market study of the global melanocyte protein PMEL market is incorporated by extensive primary and secondary research conducted by the research team at OMR. Secondary research has been conducted to refine the available data to break down the market into various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to our reports.

Secondary Sources Include:

  • Financial reports of companies involved in the market.
  • Whitepapers, research papers, and news blogs.
  • Company websites and their product catalog.

The report provides an in-depth analysis of market size, intended quality of the service preferred by consumers. The report will serve as a source for a 360-degree analysis of the market thoroughly integrating different models.

Market Segmentation

1. Global Melanocyte Protein PMEL Market Research and Analysis by Type

2. Global Melanocyte Protein PMEL Market Research and Analysis by Application

The Report Covers:

  • Comprehensive Research Methodology of the global melanocyte protein PMEL market.
  • This report additionally includes a detailed and extensive market overview with key analyst insights.
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the global melanocyte protein PMEL market.
  • Insights about market determinants that are stimulating the global melanocyte protein PMEL market.
  • The regional distribution of forecasted revenues with detailed and extensive market segments.
  • Extensive profiles and recent developments of market players.

Table of Contents

1. Report Summary

  • Current Industry Analysis and Growth Potential Outlook
  • Impact of COVID-19 on The Global Melanocyte Protein PMEL Market
  • Recovery Scenario of Global Melanocyte Protein PMEL Market
  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. By Region

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion

3. Competitive Landscape

  • 3.1.ImmunoCellular Therapeutics, Ltd.
    • 3.1.1. Overview
    • 3.1.2. Financial Analysis
    • 3.1.3. SWOT Analysis
    • 3.1.4. Recent Developments
  • 3.2. Vault Pharma Inc.
    • 3.2.1. Overview
    • 3.2.2. Financial Analysis
    • 3.2.3. SWOT Analysis
    • 3.2.4. Recent Developments
  • 3.3. Antigen Express, Inc.
    • 3.3.1. Overview
    • 3.3.2. Financial Analysis
    • 3.3.3. Swot Analysis
    • 3.3.4. Recent Developments
  • 3.4. Immunomic Therapeutics, Inc.
    • 3.4.1. Overview
    • 3.4.2. Financial Analysis
    • 3.4.3. SWOT Analysis
    • 3.4.4. Recent Developments
  • 3.5.Scancell Holdings Plc
    • 3.5.1. Overview
    • 3.5.2. Financial Analysis
    • 3.5.3. SWOT Analysis
    • 3.5.4. Recent Developments
  • 3.6. Key Strategy Analysis
  • 3.7. Impact of Covid-19 on Key Players

4. Market Segmentation

  • 4.1. Global Melanocyte Protein PMEL Market by Type
    • 4.1.1. AE-M vaccine
    • 4.1.2. SCIB-1
    • 4.1.3. VPI-121
    • 4.1.4. Others
  • 4.2. Global Melanocyte Protein PMEL Market by Application
    • 4.2.1.Glioblastoma Multiforme
    • 4.2.2.Melanoma
    • 4.2.3. Metastatic Melanoma

5. Regional Analysis

  • 5.1. North America
    • 5.1.1. United States
    • 5.1.2. Canada
  • 5.2. Europe
    • 5.2.1.UK
    • 5.2.2.Germany
    • 5.2.3.Italy
    • 5.2.4.Spain
    • 5.2.5.France
    • 5.2.6.Rest of Europe
  • 5.3. Asia-Pacific
    • 5.3.1. China
    • 5.3.2. India
    • 5.3.3. Japan
    • 5.3.4. South Korea
    • 5.3.5. Rest of Asia-Pacific
  • 5.4. Rest of the World

6. Company Profiles

  • 6.1. Amgen Inc.
  • 6.2. Bristol Myers Squibb
  • 6.3. F. Hoffmann-La Roche Ltd.
  • 6.4. GlaxoSmithKline plc
  • 6.5. Merck & Co.
  • 6.6. Novartis AG
  • 6.7. Pfizer Inc.
  • 6.8. Regeneron Pharmaceuticals, Inc.
  • 6.9. Sun Pharmaceutical Industries Ltd.
  • 6.10. Sarabhai Piramal Pharmaceuticals Ltd.

LIST OF TABLES

  • 1. GLOBAL MELANOCYTE PROTEIN PMEL MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
  • 2. GLOBAL AE-M VACCINE MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 3. GLOBAL SCIB-1IN MELANOCYTE PROTEIN PMEL MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 4. GLOBAL VPI-121IN MELANOCYTE PROTEIN PMEL MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 5. GLOBAL OTHERS TYPE MELANOCYTE PROTEIN PMEL MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 6. GLOBAL MELANOCYTE PROTEIN PMEL MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028($ MILLION)
  • 7. GLOBAL MELANOCYTE PROTEIN PMEL FOR INGLIOBLASTOMA MULTIFORME TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028($ MILLION)
  • 8. GLOBAL MELANOCYTE PROTEIN PMEL FOR MELANOMA TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028($ MILLION)
  • 9. GLOBAL MELANOCYTE PROTEIN PMEL MARKET FOR METASTATIC MELANOMA TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 10. GLOBAL MELANOCYTE PROTEIN PMEL MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2021-2028($ MILLION)
  • 11. NORTH AMERICAN MELANOCYTE PROTEIN PMEL MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
  • 12. NORTH AMERICAN MELANOCYTE PROTEIN PMEL MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
  • 13. NORTH AMERICAN MELANOCYTE PROTEIN PMEL MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
  • 14. EUROPEAN MELANOCYTE PROTEIN PMEL MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
  • 15. EUROPEAN MELANOCYTE PROTEIN PMEL MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028($ MILLION)
  • 16. EUROPEAN MELANOCYTE PROTEIN PMEL MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
  • 17. ASIA-PACIFIC MELANOCYTE PROTEIN PMEL MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
  • 18. ASIA-PACIFIC MELANOCYTE PROTEIN PMEL MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
  • 19. ASIA-PACIFIC MELANOCYTE PROTEIN PMEL MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
  • 20. REST OF THE WORLD MELANOCYTE PROTEIN PMEL MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
  • 21. REST OF THE WORLD MELANOCYTE PROTEIN PMEL MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
  • 22. REST OF THE WORLD MELANOCYTE PROTEIN PMEL MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)

LIST OF FIGURES

  • 1. IMPACT OF COVID-19 ON GLOBAL MELANOCYTE PROTEIN PMEL MARKET, 2021-2028 ($ MILLION)
  • 2. IMPACT OF COVID-19 ON GLOBAL MELANOCYTE PROTEIN PMEL MARKET BY SEGMENT, 2021-2028 ($ MILLION)
  • 3. RECOVERY OF GLOBAL MELANOCYTE PROTEIN PMEL MARKET, 2021-2028 (%)
  • 4. GLOBAL MELANOCYTE PROTEIN PMEL MARKET SHARE BY TYPE, 2021 VS 2028 (%)
  • 5. GLOBAL AE-M VACCINE MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 6. GLOBAL SCIB-1IN MELANOCYTE PROTEIN PMEL MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 7. GLOBAL VPI-121IN MELANOCYTE PROTEIN PMEL MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 8. GLOBAL OTHER TYPE MELANOCYTE PROTEIN PMEL MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 9. GLOBAL MELANOCYTE PROTEIN PMEL MARKET SHARE BY APPLICATION, 2021 VS 2028 (%)
  • 10. GLOBAL MELANOCYTE PROTEIN PMEL FOR GLIOBLASTOMA MULTIFORME TREATMENT MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 11. GLOBAL MELANOCYTE PROTEIN PMEL FOR INMELANOMA TREATMENT MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 12. GLOBAL MELANOCYTE PROTEIN PMEL FOR METASTATIC MELANOMA TREATMENT MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 13. GLOBAL MELANOCYTE PROTEIN PMEL MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 14. US MELANOCYTE PROTEIN PMEL MARKET SIZE, 2021-2028 ($ MILLION)
  • 15. CANADA MELANOCYTE PROTEIN PMEL MARKET SIZE, 2021-2028 ($ MILLION)
  • 16. UK MELANOCYTE PROTEIN PMEL MARKET SIZE, 2021-2028 ($ MILLION)
  • 17. FRANCE MELANOCYTE PROTEIN PMEL MARKET SIZE, 2021-2028 ($ MILLION)
  • 18. GERMANY MELANOCYTE PROTEIN PMEL MARKET SIZE, 2021-2028 ($ MILLION)
  • 19. ITALY MELANOCYTE PROTEIN PMEL MARKET SIZE, 2021-2028 ($ MILLION)
  • 20. SPAIN MELANOCYTE PROTEIN PMEL MARKET SIZE, 2021-2028 ($ MILLION)
  • 21. REST OF EUROPE MELANOCYTE PROTEIN PMEL MARKET SIZE, 2021-2028 ($ MILLION)
  • 22. INDIA MELANOCYTE PROTEIN PMEL MARKET SIZE, 2021-2028 ($ MILLION)
  • 23. CHINA MELANOCYTE PROTEIN PMEL MARKET SIZE, 2021-2028 ($ MILLION)
  • 24. JAPAN MELANOCYTE PROTEIN PMEL MARKET SIZE, 2021-2028 ($ MILLION)
  • 25. SOUTH KOREA MELANOCYTE PROTEIN PMEL MARKET SIZE, 2021-2028 ($ MILLION)
  • 26. REST OF ASIA-PACIFIC MELANOCYTE PROTEIN PMEL MARKET SIZE, 2021-2028 ($ MILLION)
  • 27. REST OF THE WORLD MELANOCYTE PROTEIN PMEL MARKET SIZE, 2021-2028 ($ MILLION)